Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

competition on the Company's generic products, decreased net sales of Megace(R) ES, and lower royalty income.

Revenues for the generic products division during the three month period decreased 36.4% to $92.9 million compared with the same period in 2007 due to competitive pressure, including for fluticasone, ranitidine HCl syrup, cabergoline, and a decline in many of the Company's other products due to pricing pressures as well as lower royalties driven from ondansetron ODT. Partially offsetting the decreases were increased sales of metoprolol resulting from the launch of additional strengths in the third quarter of 2007 and various amoxicillin products. Second quarter 2008 revenue for Strativa decreased to $20.0 million from $21.6 million in the prior year due to decreased net sales of Megace(R) ES.

Par's second quarter gross margin was 22.2% of sales, compared with 33.7% in 2007. This decrease is primarily attributed to increased sales of lower margin metoprolol, lower royalty income, lower sales of higher margin products such as propranolol, and a decline in many of the Company's other generic products due to pricing pressures, tempered by higher relative sales of Megace(R) ES. The gross margin rate for Strativa was 79.3% in the second quarter of 2008 compared with 72.5% in the same period in 2007.

Research and development (R&D) expense increased $1.7 million or 11.8% to $16.0 million in the second quarter of 2008, driven primarily by an increase in on-going development costs associated with the expansion of Par's generic portfolio and includes Strativa's research costs related to the development of Zensana(TM) and an initial payment related to the in-licensing agreement with MonoSol Rx.

Second quarter selling, general and administrative (SG&A) expense increased 7.9% to $36.7 million compared with the second quarter of 2007. The increase was driven by legal fees related to ongoing litigation, including Paragraph IV litigation costs. Th
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... SANTA CLARA, Calif. , Sept. 22, 2014 ... ), the leading source of health information, today released ... that provide novel insights regarding physician and patient perspectives ...  Dr. Eric Topol , a leading authority in ... as both Editor-in-Chief of Medscape and Chief Academic Officer ...
(Date:9/22/2014)... Scientists at The University of Manchester have generated a new ... most complex of its kind ever created. , ... trying to create one for over a quarter of a ... Nature Chemistry . , Consisting of two molecular ... the structure,s interlocked molecules are tiny each triangle is ...
(Date:9/22/2014)... Sept. 22, 2014 US demand to rise ... specialty biocides is forecast to rise 3.9 percent per ... demand is projected to increase 1.3 percent per year ... strong rebound in construction expenditures will support demand for ... markets, while growth in consumer spending and manufacturing output ...
(Date:9/22/2014)... 2014 Invisible Sentinel Inc., a ... food and beverage industries, announced today that its ... a non-exclusive agreement by Enartis, a global provider ... an Esseco Group company headquartered in Trecate, Italy, ... and other global markets for their own in-winery ...
Breaking Biology Technology:WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
... 2011 Double Eagle Holdings, Ltd. (OTCQB: DROP), the parent ... week a partnership with golf superstar Tiger Woods that will ... Woods and CEO of FUSE Science Adam Adler are set ... CNBC today Monday, November 21, at 12:30 p.m. during an ...
... 21, 2011 Phase I Single Dose ... and Tolerability Convergence Pharmaceuticals Limited ("Convergence"), the ... value analgesic medicines, today announces that the multiple ascending ... class calcium channel blocker CNV2197944, for the treatment of ...
... of revenues from MD Consult, First Consult subscriptions sold ... in Ethiopia Elsevier , a world-leading ... services, announced today that it will contribute to ... of Hope" campaign, providing medical assistance and support ...
Cached Biology Technology:Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement! 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 2Elsevier Supports International Crisis Aid Through 'Pillars of Hope' Campaign 3
(Date:9/21/2014)... of children with autism are significantly less likely to ... than the mothers of children who are developing normally, ... Institute has found. , Low iron intake was associated ... child if the mother was 35 or older at ... suffered from metabolic conditions such as obesity hypertension or ...
(Date:9/21/2014)... -- In recent years, new strains of bacteria have ... year, these superbugs, including drug-resistant forms of tuberculosis and ... kill at least 23,000. Despite the urgent need for ... of antibiotics in the past decade. , MIT engineers ... superbugs. Using a gene-editing system that can disable any ...
(Date:9/19/2014)... dinosaurs a newly discovered hadrosaur with a ... Rhinorex condrupus by paleontologists from North ... in what is now Utah approximately 75 million ... Rhinorex, which translates roughly into "King Nose," was ... Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Battling superbugs 2Battling superbugs 3Battling superbugs 4New hadrosaur noses into spotlight 2
... by Barry Smart published this month by SAGE challenges ... increasing consumerism. The book argues that continuing pursuit ... is socially undesirable and ecologically unsustainable. It provides a ... and its social, economic, and environmental consequences by drawing ...
... HEIDELBERG, Germany, 12 April 2010 More than 120 leading ... EMBO Meeting 2010 the second annual life sciences conference ... held in Barcelona from 4 - 7 September 2010. ... Elizabeth Blackburn Roles of telomeres & telemorase in health ...
... be applied under the Integral Coastal Zone Management (ICZM) for the ... EC Framework Progamme 7 and directed by Universitat Autnoma de Barcelona, ... four years. Researchers will be analysing 11 ... of the Adriatic Sea, and the islands of the Aegean Sea. ...
Cached Biology News:'Consumer Society' by Barry Smart 2Call for abstracts and registration the EMBO Meeting 2010 2Call for abstracts and registration the EMBO Meeting 2010 3Birth of a scientific project to save the Mediterranean coast 2Birth of a scientific project to save the Mediterranean coast 3Birth of a scientific project to save the Mediterranean coast 4